These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 32987122)
21. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective. Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283 [TBL] [Abstract][Full Text] [Related]
23. Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using Escherichia coli host cell machinery. Kalim M; Chen J; Wang S; Lin C; Ullah S; Liang K; Ding Q; Chen S; Zhan J Immunol Lett; 2017 Oct; 190():34-41. PubMed ID: 28684274 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of PDL1 positive cancer cell-specific binding activity of recombinant anti-PDL1 scFv. Kim SH; Park HM; Jeong HJ Biotechnol Prog; 2024; 40(3):e3439. PubMed ID: 38377106 [TBL] [Abstract][Full Text] [Related]
25. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy. Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821 [TBL] [Abstract][Full Text] [Related]
26. Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy. Liu H; Bi X; Zhou Y; Shi R; Yao S; Qi J; Feng H; Feng M; Yan J; Tan S Signal Transduct Target Ther; 2020 Aug; 5(1):158. PubMed ID: 32839442 [No Abstract] [Full Text] [Related]
27. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
28. Expression and purification of a novel therapeutic single-chain variable fragment antibody against BNP from inclusion bodies of Escherichia coli. Bu D; Zhou Y; Tang J; Jing F; Zhang W Protein Expr Purif; 2013 Dec; 92(2):203-7. PubMed ID: 24128692 [TBL] [Abstract][Full Text] [Related]
29. Kinetics of pH-dependent interactions between PD-1 and PD-L1 immune checkpoint proteins from molecular dynamics. Klyukin K; Alexandrov V Proteins; 2020 Sep; 88(9):1162-1168. PubMed ID: 32105362 [TBL] [Abstract][Full Text] [Related]
30. Development of an in vitro assay for screening programmed death receptor-1/programmed cell death ligand 1 monoclonal antibody therapy in dogs. Mizuno T; Kato M; Tsukui T; Igase M Vet Immunol Immunopathol; 2024 Aug; 274():110792. PubMed ID: 38878679 [TBL] [Abstract][Full Text] [Related]
31. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259 [TBL] [Abstract][Full Text] [Related]
32. Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591. Parker SA; Diaz IL; Anderson KA; Batt CA Protein Expr Purif; 2013 Jun; 89(2):136-45. PubMed ID: 23500147 [TBL] [Abstract][Full Text] [Related]
34. Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies. Gupta V; Sudhakaran IP; Islam Z; Vaikath NN; Hmila I; Lukacsovich T; Kolatkar PR; El-Agnaf OMA PLoS One; 2020; 15(11):e0241773. PubMed ID: 33156828 [TBL] [Abstract][Full Text] [Related]
35. Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach. Paciotti R; Agamennone M; Coletti C; Storchi L J Comput Aided Mol Des; 2020 Aug; 34(8):897-914. PubMed ID: 32185582 [TBL] [Abstract][Full Text] [Related]
36. Soluble production of a biologically active single-chain antibody against murine PD-L1 in Escherichia coli. Drees JJ; Augustin LB; Mertensotto MJ; Schottel JL; Leonard AS; Saltzman DA Protein Expr Purif; 2014 Feb; 94():60-6. PubMed ID: 24215864 [TBL] [Abstract][Full Text] [Related]
37. Bacterial expression and characterization of an anti-CD22 single-chain antibody fragment. Mikiewicz D; Łukasiewicz N; Zieliński M; Cecuda-Adamczewska V; Bierczyńska-Krzysik A; Romanik-Chruścielewska A; Kęsik-Brodacka M Protein Expr Purif; 2020 Jun; 170():105594. PubMed ID: 32032771 [TBL] [Abstract][Full Text] [Related]
38. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Zak KM; Kitel R; Przetocka S; Golik P; Guzik K; Musielak B; Dömling A; Dubin G; Holak TA Structure; 2015 Dec; 23(12):2341-2348. PubMed ID: 26602187 [TBL] [Abstract][Full Text] [Related]
39. Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity. Shrestha R; Garrett SC; Almo SC; Fiser A Structure; 2019 May; 27(5):829-836.e3. PubMed ID: 30930066 [TBL] [Abstract][Full Text] [Related]
40. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. Wang Z; Wu X Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]